Authors' response: Re: Reifferscheid et al., "COVID-19 vaccine uptake and intention during pregnancy in Canada"

被引:0
|
作者
MacDonald, Shannon E. [1 ]
Reifferscheid, Laura [1 ]
Bettinger, Julie A. [2 ]
Robinson, Joan [3 ]
Sadarangani, Manish [2 ,4 ]
Dube, Eve [5 ,6 ]
MacDonald, Noni E. [7 ]
Marfo, Emmanuel [1 ]
Assi, Ali [1 ]
Gagneur, Arnaud [8 ,9 ]
Driedger, S. Michelle [10 ]
机构
[1] Univ Alberta, Fac Nursing, Edmonton, AB, Canada
[2] Univ British Columbia, BC Childrens Hosp Res Inst, Vaccine Evaluat Ctr, Vancouver, BC, Canada
[3] Univ Alberta, Dept Pediat, Edmonton, AB, Canada
[4] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada
[5] Inst Natl Sante Publ Quebec, Quebec City, PQ, Canada
[6] Univ Laval, Dept Anthropol, Quebec City, PQ, Canada
[7] Dalhousie Univ, Dept Pediat, Halifax, NS, Canada
[8] CHUS, Ctr Rech, Sherbrooke, PQ, Canada
[9] Univ Sherbrooke, Dept Pediat, Sherbrooke, PQ, Canada
[10] Univ Manitoba, Rady Fac Hlth Sci, Dept Community Hlth Sci, Winnipeg, MB, Canada
基金
加拿大健康研究院;
关键词
COVID-19; Immunization; Intention; Pandemic; Pregnancy; Uptake; Vaccination;
D O I
10.17269/s41997-022-00657-1
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective: To investigate COVID-19 vaccine uptake and intent among pregnant people in Canada, and determine associated factors. Methods: We conducted a national cross-sectional survey among pregnant people from May 28 through June 7, 2021 (n = 193). Respondents completed a questionnaire to determine COVID-19 vaccine acceptance (defined as either received or intend to receive a COVID-19 vaccine during pregnancy), factors associated with vaccine acceptance, and rationale for accepting/not accepting the vaccine. Results: Of 193 respondents, 57.5% (n = 111) reported COVID-19 vaccine acceptance. Among those who did not accept the vaccine, concern over vaccine safety was the most commonly cited reason (90.1%, n = 73), and 81.7% (n = 67) disagreed with receiving a vaccine that had not been tested in pregnant people. Confidence in COVID-19 vaccine safety (aOR 16.72, 95% CI: 7.22, 42.39), Indigenous self-identification (aOR 11.59, 95% CI: 1.77, 117.18), and employment in an occupation at high risk for COVID-19 exposure excluding healthcare (aOR 4.76, 95% CI: 1.32, 18.60) were associated with vaccine acceptance. Perceived personal risk of COVID-19 disease was not associated with vaccine acceptance in the multivariate model. Conclusion: Vaccine safety is a primary concern for this population. Safety information should be communicated to this population as it emerges, along with clear messaging on the benefits of vaccination, as disease risk is either poorly understood or poorly valued in this population. © 2022, The Author(s).
引用
收藏
页码:560 / 561
页数:2
相关论文
共 50 条
  • [1] Authors’ response: Re: Reifferscheid et al., “COVID-19 vaccine uptake and intention during pregnancy in Canada”
    Shannon E. MacDonald
    Laura Reifferscheid
    Julie A. Bettinger
    Joan Robinson
    Manish Sadarangani
    Eve Dubé
    Noni E. MacDonald
    Emmanuel Marfo
    Ali Assi
    Arnaud Gagneur
    S. Michelle Driedger
    Canadian Journal of Public Health, 2022, 113 : 560 - 561
  • [2] Re: Reifferscheid et al., “COVID-19 vaccine uptake and intention during pregnancy in Canada”
    Pathum Sookaromdee
    Viroj Wiwanitkit
    Canadian Journal of Public Health, 2022, 113 : 559 - 559
  • [3] Re: Reifferscheid et al., "COVID-19 vaccine uptake and intention during pregnancy in Canada"
    Sookaromdee, Pathum
    Wiwanitkit, Viroj
    CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE, 2022, 113 (04): : 559 - 559
  • [4] Reply to Letter to the Editor Re: Liu et al., Pregnancy Outcomes During the COVID-19 Pandemic in Canada, March to August 2020
    Liu, Shiliang
    Dzakpasu, Susie
    Nelson, Chantal
    Wei, Shu Qin
    Little, Julian
    Scott, Heather
    Joseph, K. S.
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY CANADA, 2022, 44 (01) : 9 - 10
  • [5] Response to Elmaraghi et al. re: "Maxillofacial Trauma Management During COVID-19: Multidisciplinary Recommendations"
    McKean, Erin
    FACIAL PLASTIC SURGERY & AESTHETIC MEDICINE, 2020, 22 (04) : 314 - 314
  • [6] Re: Remdesivir for the treatment of COVID-19 by Lee et al.
    Beccacece, Alessia
    Bartoli, Tommaso Ascoli
    Nicastri, Emanuele
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (01) : 114 - 114
  • [7] Response to Almalki et al.: Resuming endoscopy services during the COVID-19 pandemic
    Almadi, Majid A.
    Aljebreen, Abdulrahman M.
    Azzam, Nahla
    Batwa, Faisal
    SAUDI JOURNAL OF GASTROENTEROLOGY, 2020, 26 (05): : 285 - 286
  • [8] Re: "Maxillofacial Trauma Management During COVID-19: Multidisciplinary Recommendations," by Edwards et al. and "A Guide to Facial Trauma Triage and Precautions in the COVID-19 Pandemic" by Hsieh et al.
    Elmaraghi, Shady
    Rao, Venkat K.
    Mount, Delora L.
    FACIAL PLASTIC SURGERY & AESTHETIC MEDICINE, 2020, 22 (04) : 313 - 314
  • [9] Response to Elmaraghi et al. re: "A Guide to Facial Trauma Triage and Precautions in the COVID-19 Pandemic"
    Hsieh, Tsung-yen
    Chiao, Whitney
    Hilger, Peter A.
    FACIAL PLASTIC SURGERY & AESTHETIC MEDICINE, 2020, 22 (04) : 314 - 314
  • [10] Authors’ Reply to Vrachatis et al. “Pharmaco-Immunomodulatory Therapy in COVID-19”
    John G. Rizk
    Kamyar Kalantar-Zadeh
    Mandeep R. Mehra
    Carl J. Lavie
    Youssef Rizk
    Donald N. Forthal
    Drugs, 2020, 80 : 1501 - 1503